Cargando…

Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions

BACKGROUND: Using of CD10 in accordance with clinical and histological features of thyroid lesions could be used as both diagnostic and prognostic tool, which consequently influence the management and their prognosis for survival of patients with thyroid neoplasms especially papillary thyroid carcin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mokhtari, Mojgan, Ameri, Farahnaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219203/
https://www.ncbi.nlm.nih.gov/pubmed/25371863
http://dx.doi.org/10.4103/2277-9175.143241
_version_ 1782342552877268992
author Mokhtari, Mojgan
Ameri, Farahnaz
author_facet Mokhtari, Mojgan
Ameri, Farahnaz
author_sort Mokhtari, Mojgan
collection PubMed
description BACKGROUND: Using of CD10 in accordance with clinical and histological features of thyroid lesions could be used as both diagnostic and prognostic tool, which consequently influence the management and their prognosis for survival of patients with thyroid neoplasms especially papillary thyroid carcinoma (PTC). The aim of this study was to determine its expression in PTC and different benign thyroid lesions. MATERIALS AND METHODS: In this descriptive-analytic, cross-sectional study, paraffin-embedded tissues of patients with definitive pathologic diagnosis of different benign thyroid lesions and PTC were retrieved. Immunostained sections of each slides was performed using immunohistochemistry methods and expression of CD10 was compared in two groups of benign thyroid lesions and PTC. RESULTS: From selected cases 134 sections studied in two groups of PTC (n = 67) and benign thyroid lesions (n = 67). CD10 were immunohistochemically positive in 29.9% of PTC cases, but in none of the thyroid benign lesions (0%) (P < 0.001). There was not significant relationship between expression of CD10 with age and sex of the studied population (P > 0.05). CONCLUSION: The results of the current study indicate that due to the higher expression of CD10 in PTC than benign thyroid lesions it might be used for differentiating mentioned lesions. But for using it as a diagnostic tool further studies with larger sample size and determination of its sensitivity, specificity and cut-off point is necessary.
format Online
Article
Text
id pubmed-4219203
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-42192032014-11-04 Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions Mokhtari, Mojgan Ameri, Farahnaz Adv Biomed Res Original Article BACKGROUND: Using of CD10 in accordance with clinical and histological features of thyroid lesions could be used as both diagnostic and prognostic tool, which consequently influence the management and their prognosis for survival of patients with thyroid neoplasms especially papillary thyroid carcinoma (PTC). The aim of this study was to determine its expression in PTC and different benign thyroid lesions. MATERIALS AND METHODS: In this descriptive-analytic, cross-sectional study, paraffin-embedded tissues of patients with definitive pathologic diagnosis of different benign thyroid lesions and PTC were retrieved. Immunostained sections of each slides was performed using immunohistochemistry methods and expression of CD10 was compared in two groups of benign thyroid lesions and PTC. RESULTS: From selected cases 134 sections studied in two groups of PTC (n = 67) and benign thyroid lesions (n = 67). CD10 were immunohistochemically positive in 29.9% of PTC cases, but in none of the thyroid benign lesions (0%) (P < 0.001). There was not significant relationship between expression of CD10 with age and sex of the studied population (P > 0.05). CONCLUSION: The results of the current study indicate that due to the higher expression of CD10 in PTC than benign thyroid lesions it might be used for differentiating mentioned lesions. But for using it as a diagnostic tool further studies with larger sample size and determination of its sensitivity, specificity and cut-off point is necessary. Medknow Publications & Media Pvt Ltd 2014-10-20 /pmc/articles/PMC4219203/ /pubmed/25371863 http://dx.doi.org/10.4103/2277-9175.143241 Text en Copyright: © 2014 Mokhtari. http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Article
Mokhtari, Mojgan
Ameri, Farahnaz
Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions
title Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions
title_full Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions
title_fullStr Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions
title_full_unstemmed Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions
title_short Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions
title_sort diagnostic value of cd-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219203/
https://www.ncbi.nlm.nih.gov/pubmed/25371863
http://dx.doi.org/10.4103/2277-9175.143241
work_keys_str_mv AT mokhtarimojgan diagnosticvalueofcd10markerindifferentiatingofpapillarythyroidcarcinomafrombenignthyroidlesions
AT amerifarahnaz diagnosticvalueofcd10markerindifferentiatingofpapillarythyroidcarcinomafrombenignthyroidlesions